Patents Represented by Attorney, Agent or Law Firm J. Scott Elmer
  • Patent number: 7241442
    Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: July 10, 2007
    Assignee: St. Jude Children's Research Hospital
    Inventors: Alessandra D'Azzo, Erik Jacobus Bonten
  • Patent number: 7232670
    Abstract: The present invention is based on the discovery that proteins produced in insect cell cultures are glycosylated in a unique manner that causes them to be selectively imported by cells that express mannose receptors on their membranes, particularly macrophages. Proteins that are selectively imported into cells containing mannose receptors are provided, as well as pharmaceutical compositions containing such proteins and methods for producing such proteins. Application of the present invention to produce proteins useful for treating lysosomal storage disorders is also disclosed. Engineering of cells to express mannose receptors so that they will selectively import proteins produced in insect cells is also taught, as well as a protein targeting system using such cells and proteins. Finally, an improved elution buffer for the purification of proteins produced in insect cells from a Concanavalin A column is provided.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: June 19, 2007
    Assignee: St. Jude Children's Research Hospital
    Inventors: Alessandra D'Azzo, Erik Jacobus Bonten
  • Patent number: 6623931
    Abstract: Allelic variation in the vex2, pep27 and vncS genes of bacteria responsible for tolerance to antibiotics such as penicillin and vancomycin, is taught. Methods for identifying antibiotic tolerant bacteria and subjects infected with such bacteria, particularly antibiotic tolerant Streptococcus pneumoniae, are provided. Test kits and components useful for performing such methods, particularly including oligonucleotide primers, are also provided.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: September 23, 2003
    Assignee: St. Jude Children's Research Hospital
    Inventors: Robyn M. Atkinson, Elaine I. Tuomanen
  • Patent number: 6180794
    Abstract: A method for preparing 1,2-dihydroquinolines that is more flexible than the Skraup reaction is provided. The method comprises treating an ortho-alkenyl aniline with a ketone in the presence of a Lewis acid. Novel intermediates and products of this method useful as steroid receptor modulators, as well as pharmaceutical compositions and methods of use thereof are also claimed.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: January 30, 2001
    Assignee: Ligand Pharmacueticals Incorparated
    Inventors: James P. Edwards, Todd K. Jones, Josef D. Riggenberg, Erick M. Carreira
  • Patent number: 6172241
    Abstract: A method for preparing 1,2-dihydroquinolines that is more flexible than the Skraup reaction is provided. The method comprises treating an ortho-alkenyl aniline with a ketone in the presence of a Lewis acid. Novel intermediates and products of this method useful as steroid receptor modulators, as well as pharmaceutical compositions and methods of use thereof are also claimed.
    Type: Grant
    Filed: October 15, 1999
    Date of Patent: January 9, 2001
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P. Edwards, Todd K. Jones, Josef D. Riggenberg, Erick M. Carreira
  • Patent number: 6121450
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: September 19, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Todd K. Jones, David T. Winn, Lawrence G. Hamann, Lin Zhi, Luc J. Farmer, Robert L. Davis
  • Patent number: 6093826
    Abstract: A method for preparing C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-.function.]quinolines from a lactol precursor is provided. The method comprises converting the lactol to one of a select number of mixed acetal derivatives, and then treating the acetals with a Grignard reagent. The new process provides products in higher yield and greater purity. Novel intermediates of this method are also claimed.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: July 25, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P. Edwards, Todd K. Jones
  • Patent number: 6093821
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: July 25, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Todd K. Jones, Mark E. Goldman, Charlotte L. F. Pooley, David T. Winn, James P. Edwards, Sarah J. West, Christopher M. Tegley, Lin Zhi
  • Patent number: 6083977
    Abstract: Novel trienoic retinoid compounds having activity for retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 4, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Marcus F. Boehm, Lin Zhang, Alex M. Nadzan
  • Patent number: 6017924
    Abstract: Non-steroidal compounds that are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonist, partial agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: January 25, 2000
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: James P Edwards, Robert Higuchi, Todd K Jones, Lawrence G Hamann
  • Patent number: 6005007
    Abstract: Dienoic retinoids having activity for retinoid X receptors or are panagonists on retinoic acid receptors and retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such compounds and methods for their therapeutic use.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: December 21, 1999
    Inventors: Luc J. Farmer, Lin Zhi
  • Patent number: 5994544
    Abstract: Non-steroidal compounds which are high affinity, high selectivity modulators for steroid receptors and the method of preparing these compounds are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring steroid receptor agonist or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the steroid receptor modulator compounds.
    Type: Grant
    Filed: October 8, 1997
    Date of Patent: November 30, 1999
    Assignee: Ligand Pharmaceuticals Incorporated
    Inventors: Todd K. Jones, Christopher M. Tegley, Lin Zhi, James P. Edwards
  • Patent number: 5814517
    Abstract: The present invention provides oligonucleotide sequences comprising DNA regulatory elements of the general sequence TTN.sub.X AA that bind activated transcriptional regulatory proteins in response to signaling molecules, such as cytokines. Further, the present invention also provides DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, and methods of using the DNA constructs and transfected cells to provide for the controlled expression of structural genes, for the detection and recovery of transcriptional regulatory proteins, and for measuring the ability of compounds to act as agonist and antagonists of gene transcription.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: September 29, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: H. Martin Seidel, I. Peter Lamb
  • Patent number: 5770383
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Youssef L. Bennani, Stacie S. Canan Koch, Beth Ann Badea, Jonathan J. Hebert, Luc J. Farmer, Alex M. Nadzan
  • Patent number: 5770378
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Youssef L. Bennani, Stacie S. Canan Koch, Beth Ann Badea, Jonathan J. Hebert, Alex M. Nadzan
  • Patent number: 5770382
    Abstract: Tricyclic retinoids having activity for retinoic acid receptors and/or retinoid X receptors are provided. Also provided are pharmaceutical compositions incorporating such tricyclic retinoid compounds and methods for their therapeutic use.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 23, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Chan Kou Hwang, Steven K. White, Beth Ann Badea, Alex M. Nadzan
  • Patent number: 5712094
    Abstract: The present invention provides DNA constructs that contain oligonucleotide sequences comprising DNA regulatory elements of the general sequence TTN.sub.x AA that bind activated transcriptional regulatory proteins in response to signaling molecules, such as cytokines, an operably linked promoter and operably linked heterologous gene. The present invention also provides host cells transfected with such DNA constructs, as well as methods for measuring the ability of compounds to act as agonists and antagonists of gene transcription utilizing these DNA constructs and transfected host cells.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: January 27, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: H. Martin Seidel, I. Peter Lamb, Shin-Shay Tian Chan
  • Patent number: 5707803
    Abstract: The present invention provides oligonucleotide sequences comprising DNA regulatory elements comprising point mutations of Ly6E GAS element that bind activated transcriptional regulatory proteins in response to signaling molecules, such as cytokines. Further, the present invention also provides DNA constructs comprising the oligonucleotide sequences, cells transfected with the DNA constructs, and methods of using the DNA constructs and transfected cells to provide for the controlled expression of structural genes, for the detection and recovery of transcriptional regulatory proteins, and for measuring the ability of compounds to act as agonist and antagonists of gene transcription.
    Type: Grant
    Filed: March 27, 1995
    Date of Patent: January 13, 1998
    Assignee: Ligand Pharmaceuticals, Inc.
    Inventors: Ian Peter Lamb, H. Martin Seidel